IGFBP3 and cancer: Sensitivity of 68.4% and 76.3% and specificity of 67.7% and 70.7%, respectively, for IGFBP2 and IGFBP3 in detecting early-stage PDAC. IGFBP2 associated with increased risk of diseases of pancreatic malignancy. Combination of IGFBP2 and IGFBP3 with CA 19-9 with an AUC of 0.90.